litlas
ログインアカウント作成

Kohei Shitara

2009–2026 年に発表

237
論文数
33,144
被引用数
81
h 指数
204
i10 指数

被引用数

Kohei Shitara の年別被引用数2003 年: 被引用 1 件2010 年: 被引用 2 件2011 年: 被引用 3 件2012 年: 被引用 15 件2013 年: 被引用 14 件2014 年: 被引用 15 件2015 年: 被引用 17 件2016 年: 被引用 16 件2017 年: 被引用 47 件2018 年: 被引用 92 件2019 年: 被引用 635 件2020 年: 被引用 1,228 件2021 年: 被引用 1,690 件2022 年: 被引用 1,950 件2023 年: 被引用 1,887 件2024 年: 被引用 3,283 件2025 年: 被引用 1,915 件2026 年: 被引用 63 件2004〜2009 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図中国: 引用元論文 2,975 件、この内訳の 25.6%アメリカ合衆国: 引用元論文 2,053 件、この内訳の 17.7%日本: 引用元論文 943 件、この内訳の 8.1%イタリア: 引用元論文 568 件、この内訳の 4.9%イギリス: 引用元論文 476 件、この内訳の 4.1%ドイツ: 引用元論文 446 件、この内訳の 3.8%韓国: 引用元論文 399 件、この内訳の 3.4%フランス: 引用元論文 374 件、この内訳の 3.2%スペイン: 引用元論文 325 件、この内訳の 2.8%オランダ: 引用元論文 214 件、この内訳の 1.9%カナダ: 引用元論文 190 件、この内訳の 1.6%オーストラリア: 引用元論文 189 件、この内訳の 1.6%
0%25.6%その他 21.3%

機関

分野

  • Medicine69%
  • Biochemistry, Genetics and Molecular Biology15.9%
  • Immunology and Microbiology10.4%
  • Neuroscience1.6%
  • Engineering1.5%
  • Materials Science0.5%
  • その他1.1%

トピック

  • Cancer Immunotherapy and Biomarkers13.2%
  • Gastric Cancer Management and Outcomes5.9%
  • Immune Cell Function and Interaction4.2%
  • Immunotherapy and Immune Responses3.7%
  • Immune cells in cancer3.7%
  • Colorectal Cancer Treatments and Studies3.6%
  • その他65.7%

共著者

全論文

検索で開く
  1. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

    著者: Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yañez, Mustapha Tehfé, Rubén Dario Kowalyszyn, Michalis V. Karamouzis, Ricardo Brugés, Thomas Zander, Roberto Pazo-Cid, Erika Hitre, Kynan Feeney, James M. Cleary, Valerie Poulart, Dana Cullen, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Jaffer A. Ajani - The Lancet 2021 被引用: 2,927

  2. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

    著者: Shogo Kumagai, Shohei Koyama, Kota Itahashi, Tokiyoshi Tanegashima, Yi-Tzu Lin, Yosuke Togashi, Takahiro Kamada, Takuma Irie, Genki Okumura, Hidetoshi Kono, Daisuke Ito, Rika Fujii, Sho Watanabe, Atsuo Sai, Shota Fukuoka, Eri Sugiyama, Go Watanabe, Takuya Owari, Hitomi Nishinakamura, Daisuke Sugiyama, Yuka Maeda, Akihito Kawazoe, Hiroki Yukami, Keigo Chida, Yuuki Ohara, Tatsuya Yoshida, Yuki Shinno, Yuki Takeyasu, Masayuki Shirasawa, Kenta Nakama, Keiju Aokage, Jun Suzuki, Genichiro Ishii, Takeshi Kuwata, Naoya Sakamoto, Masahito Kawazu, Toshihide Ueno, Taisuke Mori, Naoya Yamazaki, Masahiro Tsuboi, Yasushi Yatabe, Takahiro Kinoshita, Toshihiko Doi, Kohei Shitara, Hiroyuki Mano, Hiroyoshi Nishikawa - Cancer Cell 2022 被引用: 838

  3. Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

    著者: Yosuke Togashi, Kohei Shitara, Hiroyoshi Nishikawa - Nature Reviews Clinical Oncology 2019 被引用: 1,536

  4. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

    著者: Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min‐Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kensei Yamaguchi - New England Journal of Medicine 2020 被引用: 1,304

  5. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

    著者: Kohei Shitara, Florian Lordick, Yung‐Jue Bang, Peter C. Enzinger, David H. Ilson, Manish A. Shah, Eric Van Cutsem, Rui‐Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon‐Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan M. Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani - The Lancet 2023 被引用: 711

  6. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

    著者: Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang, Charles S. Fuchs, Lucjan Wyrwicz, Keun‐Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R. Castro, Wasat Mansoor, Maria Ignez Braghiroli, Nina Karaseva, Christian Caglevic, Luis J. Villanueva-Rivera, Eray Goekkurt, Hironaga Satake, Peter C. Enzinger, María Alsina, Al B. Benson, Joseph Chao, Andrew H. Ko, Zev A. Wainberg, Uma Kher, Sukrut Shah, Soonmo Peter Kang, Josep Tabernero - JAMA Oncology 2020 被引用: 1,125

  7. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

    著者: Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu, Do‐Youn Oh, Sang Cheul Oh, Hyun Cheol Chung, Keun-Wook Lee, Takeshi Omori, Kohei Shitara, Shinichi Sakuramoto, Ik‐Joo Chung, Kensei Yamaguchi, Ken Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jen‐Shi Chen, Li‐Yuan Bai, Sung‐Yong Oh, Yasuhiro Choda, Hisateru Yasui, Kentaro Takeuchi, Yoshinori Hirashima, Shunsuke Hagihara, Narikazu Boku - The Lancet Oncology 2022 被引用: 768

  8. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

    著者: Shogo Kumagai, Yosuke Togashi, Takahiro Kamada, Eri Sugiyama, Hitomi Nishinakamura, Yoshiko Takeuchi, Vitaly Kochin, Kota Itahashi, Yuka Maeda, Shigeyuki Matsui, Takuma Shibahara, Yasuho Yamashita, Takuma Irie, Ayaka Tsuge, Shota Fukuoka, Akihito Kawazoe, Hibiki Udagawa, Keisuke Kirita, Keiju Aokage, Genichiro Ishii, Takeshi Kuwata, Kenta Nakama, Masahito Kawazu, Toshihide Ueno, Naoya Yamazaki, Kōichi Goto, Masahiro Tsuboi, Hiroyuki Mano, Toshihiko Doi, Kohei Shitara, Hiroyoshi Nishikawa - Nature Immunology 2020 被引用: 812

  9. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

    著者: Manish A. Shah, Kohei Shitara, Jaffer A. Ajani, Yung‐Jue Bang, Peter C. Enzinger, David H. Ilson, Florian Lordick, Eric Van Cutsem, Javier Gállego, Jing Huang, Lin Shen, Sang Cheul Oh, Patrapim Sunpaweravong, Hwoei Fen Soo Hoo, Hacı Mehmet Türk, Mok Oh, Jung Wook Park, Diarmuid Moran, Pranob Bhattacharya, Ahsan M. Arozullah, Rui‐Hua Xu - Nature Medicine 2023 被引用: 551

  10. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

    著者: Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I. Jalal, Manish A. Shah, Jean-Phillipe Metges, Marcelo Garrido, Talia Golan, Mario Mandalà, Zev A. Wainberg, Daniel V.T. Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H. Ko, Geoffrey Y. Ku, Philip Philip, Peter C. Enzinger, Yung‐Jue Bang, Diane Levitan, Jiangdian Wang, Minori Koshiji Rosales, Rita P. Dalal, Harry H. Yoon - JAMA Oncology 2018 被引用: 1,812

  11. PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

    著者: Takahiro Kamada, Yosuke Togashi, Christopher Tay, Danbee Ha, Akinori Sasaki, Yoshiaki Nakamura, Eiichi Sato, Shota Fukuoka, Yasuko Tada, Atsushi Tanaka, Hiromasa Morikawa, Akihito Kawazoe, Takahiro Kinoshita, Kohei Shitara, Shimon Sakaguchi, Hiroyoshi Nishikawa - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 被引用: 1,029

  12. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

    著者: Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez, Ning Li, Sara Lonardi, О. P. Коlesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan Wyrwicz, Jianming Xu, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Sukrut Shah, Pooja Bhagia, Hyun Cheol Chung - Nature 2021 被引用: 709

  13. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

    著者: Yelena Y. Janjigian, Akihito Kawazoe, Yuxian Bai, Jianming Xu, Sara Lonardi, Jean Phillipe Metges, Patricio Yañez, Lucjan Wyrwicz, Lin Shen, Yuriy Ostapenko, Mehmet Bilici, Hyun Cheol Chung, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Kan Li, Chie‐Schin Shih, Pooja Bhagia, Sun Young Rha - The Lancet 2023 被引用: 467

  14. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

    著者: Kohei Shitara, Jaffer A. Ajani, Markus Moehler, Marcelo Garrido, Carlos Gallardo, Lin Shen, Kensei Yamaguchi, Lucjan Wyrwicz, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshu Liu, Mustapha Tehfé, Elena Elimova, Ricardo Brugés, Thomas Zander, Sérgio de Azevedo, Rubén Dario Kowalyszyn, Roberto Pazo-Cid, Michael Schenker, James M. Cleary, Patricio Yañez, Kynan Feeney, Michalis V. Karamouzis, Valerie Poulart, Ming Lei, Hong Xiao, Kaoru Kondo, Mingshun Li, Yelena Y. Janjigian - Nature 2022 被引用: 442

  15. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

    著者: Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Akihito Kawazoe, Masako Asayama, Takako Yoshii, Daisuke Kotani, Hitomi Tamura, Yuichi Mikamoto, Nami Hirano, Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Takeshi Kuwata, Yosuke Togashi, Hiroyoshi Nishikawa, Kohei Shitara - Journal of Clinical Oncology 2020 被引用: 926

  16. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    著者: Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min‐Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun Cheol Chung, Kei Muro, Eray Goekkurt, Wasat Mansoor, Raymond S McDermott, Einat Shacham‐Shmueli, Xinqun Chen, Carlos Mayo, Soonmo Peter Kang, Atsushi Ohtsu, Charles S. Fuchs, Guillermo Lerzo, Juan Manuel O’Connor, Guillermo Ariel Mendez, James Lynam, Niall C. Tebbutt, Mark Wong, Andrew Strickland, Christos S. Karapetis, David Goldstein, Paul L. Vasey, Jean–Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Müller, Felipe Rey, Ángela R. Zambrano, Joaquín Guerra, Merete Krogh, Lene Bæksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Päivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Eray Goekkurt, Thomas Hoehler, Georg Martin Haag, Salah‐Eddin Al‐Batran, Hugo R. Castro, Karla Alejandra Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinéad Cuffe, Cathy Kelly, Ravit Geva, Einat Shacham‐Shmueli, Ayala Hubert, Alex Beny, Baruch Brenner, Giuseppe Aprile, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chìn, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernández Hernández, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Olav Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Z. Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay ほか 58 名 - The Lancet 2018 被引用: 1,316

  17. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

    著者: Toshihiko Doi, Kohei Shitara, Yoichi Naito, Akihiko Shimomura, Yasuhiro Fujiwara, Kan Yonemori, Chikako Shimizu, Tatsunori Shimoi, Yasutoshi Kuboki, Nobuaki Matsubara, Atsuko Kitano, Takahiro Jikoh, Caleb Lee, Yoshihiko Fujisaki, Yusuke Ogitani, Antoine Yver, Kenji Tamura - The Lancet Oncology 2017 被引用: 501

  18. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

    著者: Joseph Chao, Charles S. Fuchs, Kohei Shitara, Josep Tabernero, Kei Muro, Eric Van Cutsem, Yung‐Jue Bang, Ferdinando De Vita, Gregory Landers, Chia‐Jui Yen, Ian Chau, Anneli Elme, Jeeyun Lee, Mustafa Özgüroğlu, Daniel V.T. Catenacci, Harry H. Yoon, Erluo Chen, David E. Adelberg, Chie‐Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg - JAMA Oncology 2021 被引用: 443

  19. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

    著者: Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz, Takashi Oshima, Nina Karaseva, M. A. Osipov, Hisateru Yasui, Hiroshi Yabusaki, S. G. Afanasyev, Young Kyu Park, Salah-Eddin Al-Batran, Takaki Yoshikawa, Patricio Yañez, Maria Di Bartolomeo, Sara Lonardi, Josep Tabernero, Eric Van Cutsem, Yelena Y. Janjigian, Do‐Youn Oh, Jianming Xu, Xiao Fang, Chie‐Schin Shih, Pooja Bhagia, Yung‐Jue Bang - The Lancet Oncology 2023 被引用: 339

  20. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells

    著者: Shogo Kumagai, Yosuke Togashi, Chika Sakai, Akihito Kawazoe, Masahito Kawazu, Toshihide Ueno, Eiichi Sato, Takeshi Kuwata, Takahiro Kinoshita, Masami Yamamoto, Sachiyo Nomura, Tetsuya Tsukamoto, Hiroyuki Mano, Kohei Shitara, Hiroyoshi Nishikawa - Immunity 2020 被引用: 259

  21. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer

    著者: Jun Watanabe, Kei Muro, Kohei Shitara, Kentaro Yamazaki, Manabu Shiozawa, Hisatsugu Ohori, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino - JAMA 2023 被引用: 258

  22. Claudin 18.2 as a novel therapeutic target

    著者: Izuma Nakayama, Changsong Qi, Yang Chen, Yoshiaki Nakamura, Lin Shen, Kohei Shitara - Nature Reviews Clinical Oncology 2024 被引用: 160

  23. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial

    著者: Yelena Y. Janjigian, Jaffer A. Ajani, Markus Moehler, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, James M. Cleary, Elena Elimova, Michalis V. Karamouzis, Ricardo Brugés, Tomasz Skoczylas, Arinilda Campos Bragagnoli, Tianshi Liu, Mustapha Tehfé, Thomas Zander, Rubén Dario Kowalyszyn, Roberto Pazo-Cid, Michael Schenker, Kynan Feeny, Rui Wang, Ming Lei, Clara Chen, Raheel Nathani, Kohei Shitara - Journal of Clinical Oncology 2024 被引用: 216

  24. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline

    著者: Manish A. Shah, Erin B. Kennedy, Ashley E. Alarcon-Rozas, Thierry Alcindor, Angela N. Bartley, Aubrey Belk Malowany, Nishin A. Bhadkamkar, Dana C. Deighton, Yelena Y. Janjigian, Asha Karippot, Uqba Khan, Daniel A. King, Kelsey Klute, Jill Lacy, James J. Lee, Rutika Mehta, Sarbajit Mukherjee, Arun Nagarajan, Haeseong Park, Anwaar Saeed, Thomas J. Semrad, Kohei Shitara, Elizabeth Smyth, Nataliya V. Uboha, Melani Vincelli, Zev A. Wainberg, Lakshmi Rajdev - Journal of Clinical Oncology 2023 被引用: 202